C135-LS/C144-LS
An anti-RBD (SARS-CoV-2 spike protein) antibody combination.
General information
C135-LS/C144-LS is a combination of two human monoclonal antibodies targeting RBD of the SARS-CoV-2 spike protein, both with LS mutation increasing their half-life (Schäfer et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Spike protein Animal model Antibody |
hAce2-HT1080 cells; muAce2-HT1080 cells; BALB/c mice; mouse-adapted SARS-CoV-2; Syrian hamsters; live SARS-CoV-2 (hamsters) | 11.74 | At higher dose (16 mg/kg) provided near-sterilizing effect in mice infected with mouse-adapted SARS-CoV-2. Prophylactic doses (prior to viral challenge) as low as 2 mg/kg diminished or eliminated live SARS-CoV-2 replication in Syrian hamsters; similarly, therapeutic administration (post viral challenge) mitigated infection in lung tissue below detection limit at higher doses (≥12 mg/kg) and reduced viral load 10,000-fold at the lowest dose tested (4 mg/kg). |
Nov/19/2020 |
